life'sDHA
Commercial- Indications
- Infant nutrition, Cognitive health
Company intelligence / Profile preview
By the time of its acquisition in early 2011 by DSM, Martek was a global leader in microbial-based omega‐3/omega‐6 ingredients. Its flagship product "life’sDHA™" was the only FDA-approved DHA additive for infant formula at that time. Its oils were included in over 99% of U.S. infant formulas and had significant penetration globally. The company had robust sales ($450 million FY2010), with commercialized products rather than clinical-stage therapeutics.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Martek Biosciences Corporation.